Temozolomide (brand names Temodar and Temodal Schering-Plough Corporation) is an oral alkylating agent which can be used for the treatment of Grade IV astrocytoma -- an aggressive brain tumor, also known as glioblastoma multiforme. The agent was developed by Malcolm Stevens and his team at Aston University in Birmingham, UK. A derivative of imidazotetrazine, temozolomide is the prodrug of MTIC (3-methyl-imidazole-4-carboxamide).

PropertyValue
dbpedia-owl:Drug/atcPrefix
  • L01
dbpedia-owl:Drug/atcSuffix
  • AX03
dbpedia-owl:Drug/casNumber
  • 85622-93-1
dbpedia-owl:Drug/drugbank
  • APRD00557
dbpedia-owl:Drug/iupacName
  • 4-methyl-5-oxo- 2,3,4,6,8-pentazabicyclo [4.3.0] nona-2,7,9-triene- 9-carboxamide
dbpedia-owl:Drug/pubchem
  • 5394
dbpedia-owl:atcPrefix
  • L01
dbpedia-owl:atcSuffix
  • AX03
dbpedia-owl:casNumber
  • 85622-93-1
dbpedia-owl:drugbank
  • APRD00557
dbpedia-owl:iupacName
  • 4-methyl-5-oxo- 2,3,4,6,8-pentazabicyclo [4.3.0] nona-2,7,9-triene- 9-carboxamide
dbpedia-owl:pubchem
  • 5394
dbpedia-owl:thumbnail
dbpprop:abstract
  • Temozolomide (brand names Temodar and Temodal Schering-Plough Corporation) is an oral alkylating agent which can be used for the treatment of Grade IV astrocytoma -- an aggressive brain tumor, also known as glioblastoma multiforme. The agent was developed by Malcolm Stevens and his team at Aston University in Birmingham, UK. A derivative of imidazotetrazine, temozolomide is the prodrug of MTIC (3-methyl-imidazole-4-carboxamide). It has been available in the US since August 1999, and in other countries since the early 2000s. The therapeutic benefit of temozolomide depends on its ability to alkylate/methylate DNA, which most often occurs at the N-7 or O-6 positions of guanine residues. This methylation damages the DNA and triggers the death of tumor cells. However, some tumor cells synthesize an enzyme that is able to repair this type of DNA damage, and therefore diminishes the therapeutic efficacy of temozolomide. This enzyme is called O-6-methylguanine-DNA methyltransferase or O-6-alkylguanine-DNA alkyltransferase (AGT or AGAT). In some tumors, epigenetic silencing of the MGMT/AGT gene prevents the synthesis of this enzyme, and as a consequence such tumors are more sensitive to killing by temozolomide. Conversely, the presence of MGMT protein in brain tumors predicts poor response to temozolomide and these patients receive little benefit from chemotherapy with temozolomide.
  • Temozolomid (Handelsname Temodal) ist ein alkylierendes Zytostatikum. Temozolomid wird zur simultanen, adjuvanten und gleichsam palliativen Therapie von Glioblastomen in Kombination mit Strahlentherapie eingesetzt. Als Nebenwirkungen können Thrombozytopenie und Neutropenie auftreten.
  • Temozolomid (temozolomide, L01AX) – organiczny związek chemiczny, lek przeciwnowotworowy.
dbpprop:atcPrefix
  • L01
dbpprop:atcSuffix
  • AX03
dbpprop:c
  • 6 (xsd:integer)
dbpprop:casNumber
  • 85622-93-1
dbpprop:drugbank
  • APRD00557
dbpprop:eliminationHalfLife
  • 1.8 hours
dbpprop:h
  • 6 (xsd:integer)
dbpprop:hasPhotoCollection
dbpprop:iupacName
  • 4-methyl-5-oxo- 2,3,4,6,8-pentazabicyclo [4.3.0] nona-2,7,9-triene- 9-carboxamide
dbpprop:legalUs
  • Rx-only
dbpprop:metabolism
  • spontaneously hydrolyzed at physiologic pH to the active species, 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) and to temozolomide acid metabolite.
dbpprop:molecularWeight
  • 194.151 g/mol
dbpprop:n
  • 6 (xsd:integer)
dbpprop:o
  • 2 (xsd:integer)
dbpprop:proteinBound
  • 15
dbpprop:pubchem
  • 5394 (xsd:integer)
dbpprop:reference
dbpprop:routesOfAdministration
  • Oral
dbpprop:width
  • 200 (xsd:integer)
dbpprop:wikiPageUsesTemplate
rdf:type
rdfs:comment
  • Temozolomide (brand names Temodar and Temodal Schering-Plough Corporation) is an oral alkylating agent which can be used for the treatment of Grade IV astrocytoma -- an aggressive brain tumor, also known as glioblastoma multiforme. The agent was developed by Malcolm Stevens and his team at Aston University in Birmingham, UK. A derivative of imidazotetrazine, temozolomide is the prodrug of MTIC (3-methyl-imidazole-4-carboxamide).
  • Temozolomid (Handelsname Temodal) ist ein alkylierendes Zytostatikum. Temozolomid wird zur simultanen, adjuvanten und gleichsam palliativen Therapie von Glioblastomen in Kombination mit Strahlentherapie eingesetzt. Als Nebenwirkungen können Thrombozytopenie und Neutropenie auftreten.
  • Temozolomid (temozolomide, L01AX) – organiczny związek chemiczny, lek przeciwnowotworowy.
rdfs:label
  • Temozolomide
  • Temozolomid
  • Temozolomid
owl:sameAs
skos:subject
foaf:depiction
foaf:page
is dbpprop:redirect of
is owl:sameAs of